Peptides and sport: what the rules require

Rules and evidence as of September 22, 2026. The 2026 WADA Prohibited List took effect on January 1, 2026. The Code and exemption standard have their own effective dates: publication of a future edition does not make it applicable immediately. [1] [6] [9]

The answer in three parts

• Established: the 2026 WADA list prohibits BPC-157 in and out of competition; several other named peptides are also prohibited at all times. The athlete’s sport or event must determine which rules apply. [1]

• Not automatic: a prescription, amateur status, a pre-check inquiry, or a negative drug test does not itself grant permission. USADA describes a BPC-157 exemption as unlikely, while considering applications individually. [2] [4] [5] [9]

• What can change the decision: the responsible authority can establish the applicable rules and decide whether a documented medical need meets the exemption requirements. An individual decision must cover the athlete, treatment, and event in question. [4] [5] [6]

Which peptides are on the list?

The word peptide describes a type of molecule, not one anti-doping category. USADA’s explanation of cosmetic ingredients, for example, distinguishes peptides that are not prohibited from prohibited growth factors. Neither the word on the package nor its use in a cream is sufficient to settle the question. [3]

These examples appear explicitly in the 2026 WADA list:

These are examples, not a complete list. S0 also covers qualifying pharmacological substances that lack current governmental approval for human therapeutic use and are not addressed by another section. A missing brand name does not establish permission. [1]

For a substance prohibited at all times, using it only between competitions does not remove the restriction. Equally, the existence of a medical use or prescription does not by itself grant a sporting exemption. [1] [4]

Can the rules apply to amateur athletes?

A person may think of themselves as recreational because sport is not their job. Anti-doping systems use their own definitions. Membership, competition level, governing-body rules, and previous participation can matter. An age-group entry or a lack of prize money should prompt a check rather than an assumption.

USADA’s policy distinguishes international-level athletes, national-level athletes, recreational athletes, and another defined category called sport participants. Requirements differ, and international events can introduce additional obligations. An exemption granted at one level may need recognition at another. [5]

For someone competing in a USADA-governed sport, the agency’s TUE Pre-Check, an initial check on therapeutic use exemptions, is a practical starting point. It helps establish whether an application is needed and where to send it. A pre-check inquiry is a procedural step, not an exemption grant. Athletes under another national agency, federation, league, or event should use that organization’s process. USADA’s answer is not automatically an answer for every sporting system. [4] [5]

Useful details to have ready include the sport and discipline, governing body, upcoming event, athlete classification if known, and any existing exemption. The question is, “Which rules and authority cover my situation?” A general article cannot infer the answer from someone’s age or training schedule.

Can an athlete get an exemption for BPC-157?

A therapeutic use exemption, or TUE, is a formal permission for a prohibited substance or method in defined medical circumstances. It is not a general approval of a product.

USADA says a BPC-157 TUE is unlikely because permitted alternatives are available, while also stating that it considers each application individually. That is materially different from saying that an exemption is impossible. It is also not a prediction that a particular application will succeed. [2]

Under the ordinary criteria in the International Standard for Therapeutic Use Exemptions, the applicant must establish all four points on the balance of probabilities—meaning more likely than not:

• A diagnosed medical condition requires the prohibited substance or method, supported by appropriate clinical evidence.

• Treatment is not expected to enhance performance beyond returning the athlete to normal health.

• The treatment is indicated and there is no reasonable permitted alternative.

• The medical need is not caused, wholly or partly, by earlier use without a TUE of a substance or method that was prohibited at the time. [6]

The process therefore depends on the diagnosis, clinical evidence, treatment rationale, and reasonable alternatives. A prescription alone does not establish these criteria. The standard explicitly distinguishes a TUE decision from a decision about the safest treatment or its legality in every jurisdiction. [6]

The clinician’s role is to diagnose and treat the condition and supply accurate supporting information. The relevant anti-doping authority decides the exemption. For planned care, connect those responsibilities early enough to obtain the required decision before use, unless the responsible authority confirms that a retrospective process applies. [4] [5] [6]

Retrospective applications have defined limits

Some circumstances permit a TUE application after treatment: examples include emergency care and certain situations in which an athlete was not required or permitted to apply in advance. Permission to apply retrospectively does not mean the application will be granted. A separate exceptional provision allows retrospective approval where refusing it would be manifestly unfair in light of the Code’s purpose. That decision can depart from the ordinary criteria and requires the responsible authority’s assessment; it is not an athlete’s own exemption. [6]

USADA’s policy illustrates why individualized advice matters. It may decline to process a prospective application for some recreational athletes because a later application can receive retrospective effect if granted. That is a procedural distinction, not blanket permission to use any prohibited product. [5]

Do not delay emergency treatment while trying to complete sports paperwork. USADA advises obtaining necessary emergency care first and keeping the medical records needed for subsequent review. For planned care, contact the responsible organization early enough to understand its documentation and timing requirements. [4]

A practical way to check a proposed treatment

Bring the actual product information to both the clinician and the anti-doping inquiry. A nickname such as “recovery peptide,” a clinic package name, or “research compound” can conceal the identity that matters.

First, establish the governing rules. Ask the federation or event organizer which anti-doping organization handles medication questions and exemptions. If a competition is approaching, include its name and date; do not assume an existing decision covers it.

Second, check the exact medication. Global DRO is an official medication-status resource for the countries it covers. Select the relevant sport, sporting nationality, and country of purchase as requested by the service. Match the product and ingredients, and read any conditions about route or use. Brand names can refer to different formulations in different countries. [7]

Third, retain the answer. Save the Global DRO reference number and the conditions attached to the result. The number records the search and advice given; it does not certify the product’s contents. If the product or ingredient cannot be found, contact the relevant drug-reference service. If no result appears, that does not establish permission. [7]

Fourth, resolve any exemption requirement. Use the applicable pre-check or TUE process, supplying the medical information requested. Confirm that a decision is valid for the planned event and remains within its stated conditions. [4] [5]

Global DRO does not certify supplements. Finding that a declared ingredient is permitted does not verify everything inside a supplement bottle or research-labeled vial. Product identity and quality remain separate questions. [7]

Will BPC-157 show up in a test?

Published analytical work has developed methods to detect BPC-157 and selected breakdown products in urine. A 2023 study used enzyme-containing preparations from human liver and skin to investigate metabolism. Researchers then validated a urine assay using reference compounds added to samples from volunteers. These were laboratory experiments, with no BPC-157 administration to the volunteers. [8]

The study’s stability experiment concerned stored sample extracts. It did not measure how long BPC-157 remains detectable after a person takes it. Likewise, analytical sensitivity describes the assay under its validation conditions. These findings support method development, without establishing an individual detection window or what every testing laboratory routinely measures. [8]

There is a separate rules issue. Under the World Anti-Doping Code, use of a prohibited substance can be established by reliable evidence other than a positive sample. Admissions, documents, or other evidence can therefore matter. A negative test does not create permission for prohibited use. [9]

Responsibility does not end with a recommendation

The Code places personal responsibility on athletes for prohibited substances found in their samples. For a presence violation, proving intent or fault is not required; this is often called strict liability. Fault and other circumstances can still affect the consequences. It is inaccurate to assume either that an innocent explanation automatically prevents a violation or that every case produces an identical sanction. [9]

That framework makes clear communication with a prescriber important. Tell clinicians that anti-doping rules may apply. Ask them to record the diagnosis, the exact treatment, and the clinical alternatives. A medical discussion focused on an injury may otherwise omit the sporting requirements that the athlete needs to resolve separately.

If treatment has already started, seek prompt advice from the clinician and responsible anti-doping organization. Do not independently stop a prescribed medicine merely because an online search raises a concern; changes in treatment can carry health consequences. USADA’s policy specifically advises discussing discontinuation with the athlete’s physician. [5]

How Healthy Longevity Clinic experts evaluate the evidence

An athlete seeking better recovery needs a treatment that fits the health problem and an answer about sporting eligibility. Healthy Longevity Clinic’s interpretation keeps those decisions separate. A clinician can explain the diagnosis, medical rationale, and reasonable alternatives; the relevant anti-doping authority determines which sporting rules apply and whether an exemption is granted. A prescription cannot do both jobs. [4] [5] [6]

The most consequential distinction for BPC-157 is between “unlikely” and “impossible.” USADA’s position leaves room for individual assessment, but gives no basis for assuming permission. When an athlete may apply retrospectively, that concerns the timing of an application; it does not settle its outcome. Resolving the authority, athlete category, and documentation before planned treatment is more useful than trying to infer permission from a general label such as “recovery peptide.” [2] [5] [6]

Laboratory detection research answers a third question. The 2023 study demonstrated an analytical method using human-derived material and prepared urine samples; it did not determine how long an athlete would test positive after use. That finding cannot change the sporting prohibition. What can change an individual eligibility decision is a relevant rule change or an exemption granted by the responsible authority under the applicable conditions. [1] [6] [8] [9]

Three questions to resolve before planned treatment

1. For my sport, athlete category, and next event, which organization decides medication status and exemptions?

2. What is the exact treatment for my diagnosed condition, and are reasonable permitted alternatives available?

3. Do I need an exemption before treatment, what documentation is required, and would an existing decision be recognized at my event?

Common questions

Is every peptide prohibited?

No. Peptides are a type of molecule. Status depends on the particular substance and applicable rules. Some cosmetic peptides are not prohibited, while prohibited growth factors remain subject to the rules even in a cosmetic product. [1] [3]

Does a doctor’s prescription count as an exemption?

No. A prescription addresses medical treatment; a therapeutic use exemption is a separate formal decision. The authority requires evidence that the applicable exemption criteria are met. [4] [6]

Can I use an all-times prohibited substance between events?

The prohibition applies both in and out of competition. Time between events does not remove it. Nor does a negative test establish permission: the Code also allows proof of use through other reliable evidence. [1] [9]

What if I need emergency care, or treatment has already started?

Emergency care comes first; keep the medical records for the subsequent process. For treatment already underway, seek advice promptly from the clinician and responsible anti-doping organization. Do not independently stop prescribed medication because of an online anti-doping concern. [4] [5]